Runda Medical(SH:603108)2022-04-27 16:00Financial Performance - Revenue for Q1 2022 was CNY 2,168,604,932.18, an increase of 7.34% compared to the same period last year[5] - Net profit attributable to shareholders decreased by 53.96% to CNY 41,325,857.98[5] - Basic earnings per share decreased by 54.80% to CNY 0.07[7] - Diluted earnings per share also decreased by 53.33% to CNY 0.07[10] - Net profit for Q1 2022 was CNY 79,878,924.73, a decrease of 44.73% compared to CNY 144,732,968.97 in Q1 2021[22] - The total comprehensive income attributable to the parent company in Q1 2022 was approximately ¥40.80 million, down from ¥89.27 million in Q1 2021, reflecting a decrease of about 54.3%[24] - The basic and diluted earnings per share for Q1 2022 were both ¥0.07, compared to ¥0.15 in Q1 2021, indicating a decline of approximately 53.3%[24] Cash Flow - Net cash flow from operating activities was negative at CNY -334,135,476.04, a decline of 64.86% year-on-year[5] - The net cash flow from operating activities for Q1 2022 was approximately -¥334.14 million, compared to -¥202.68 million in Q1 2021, indicating a decline in cash flow performance[25] - The net cash flow from investing activities in Q1 2022 was approximately -¥41.63 million, an improvement from -¥108.01 million in Q1 2021, showing a reduced cash outflow in investments[26] - The net cash flow from financing activities for Q1 2022 was approximately ¥140.56 million, a significant recovery from -¥3.81 million in Q1 2021, indicating improved financing conditions[26] - Net cash flow from operating activities was CNY 78,591,481.24, a significant improvement from a negative CNY 2,624,562.51 in Q1 2021[31] Assets and Liabilities - Total assets increased by 3.98% to CNY 12,495,026,652.93 compared to the end of the previous year[7] - Total assets increased to CNY 12,495,026,652.93 in Q1 2022 from CNY 12,016,544,118.64 in Q1 2021, reflecting a growth of 3.98%[19] - Total liabilities rose to CNY 8,042,302,014.70 in Q1 2022, compared to CNY 7,624,504,350.09 in Q1 2021, marking an increase of 5.49%[19] - Total assets as of March 31, 2022, included cash and cash equivalents of approximately ¥439.54 million, an increase from ¥406.61 million in the previous year[26] Shareholder Information - Total number of common shareholders at the end of the reporting period is 27,288[12] - The largest shareholder, Hangzhou Gongshu State-owned Investment Group Co., Ltd., holds 116,000,000 shares, accounting for 20.02% of total shares[12] - The company has a total of 10 major shareholders with significant stakes, including several institutional investors[12] Operational Challenges - The decline in net profit was attributed to increased market investment and prolonged settlement cycles due to pandemic-related restrictions[9] - The company faced challenges in hospital operations and demand for routine testing due to COVID-19 outbreaks in various regions[9] - The company is actively expanding its product offerings related to COVID-19, which has led to increased cash outflows for inventory purchases[9] Expenses - Total operating costs for Q1 2022 were CNY 2,056,709,943.32, up 10.65% from CNY 1,858,985,442.63 in Q1 2021[19] - Research and development expenses for Q1 2022 were CNY 31,421,115.22, up from CNY 27,379,802.57 in Q1 2021, indicating a focus on innovation[22] - The company reported a significant increase in sales expenses to CNY 223,534,983.71 from CNY 170,543,268.36 in Q1 2021, reflecting a strategy to enhance market presence[22] Inventory and Receivables - Accounts receivable increased to ¥4,146,040,883.81 from ¥3,711,086,814.42, reflecting a growth of about 11.7% year-over-year[16] - Inventory as of March 31, 2022, is ¥1,521,725,239.73, slightly up from ¥1,502,437,657.13 at the end of 2021, indicating a growth of approximately 1.5%[16] - The company reported a decrease in inventory to approximately ¥661.21 million in Q1 2022 from ¥709.03 million in Q1 2021, indicating a reduction of about 6.7%[26]